58.70
58.70 (0%)
As of Jan 22, 2024
Mirati Therapeutics, Inc. [MRTX]
Source:
Company Overview
Mirati Therapeutics, Inc. is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer.
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | 858-332-3410 |
| Industry | manufacturing |
| CEO | David D. Meek |
| Website | mirati.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $16.4 |
| Operating Profit | $-172.1 |
| Net Income | $-161.9 |
| Net Cash | $23.5 |
Profit Ratios
| Gross Margin | $14.7 |
| Operating Margin | -1,049.1 |
| Profit as % of Revenues | 89.7% |
| Profit as % of Assets | -13.9% |
| Profit as % of Stockholder Equity | -17.1% |
Management Effectiveness
| Return on Equity | -17.1% |
| Return on Assets | -14.3% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,129.7 |
| Total Liabilities | $183.2 |
| Operating Cash Flow | $-465.3 |
| Investing Cash Flow | $148.5 |
| Financing Cash Flow | $340.3 |
